Loading...
XHKG
2235
Market cap374mUSD
Jul 10, Last price  
7.25HKD
1D
1.40%
1Q
-3.07%
IPO
-76.23%
Name

MicroTech Medical Hangzhou Co Ltd

Chart & Performance

D1W1MN
XHKG:2235 chart
P/E
64.08
P/S
3.89
EPS
0.10
Div Yield, %
Shrs. gr., 5y
-1.06%
Rev. gr., 5y
54.41%
Revenues
661m
+91.19%
51,863,00075,277,000151,404,000173,543,000248,346,142345,615,000660,788,390
Net income
40m
P
-78,614,000-121,009,000-48,182,000-35,043,084-125,015,870-63,118,00040,151,697
CFO
32m
P
-17,954,000-9,575,000-44,216,000-107,674,000-152,996,092-120,646,00031,801,798

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

MicroTech Medical (Hangzhou) Co., Ltd. focuses on the innovation, production, and market distribution of essential medical devices and consumables for diabetes management. Its operations extend across the People's Republic of China and into global markets. The company offers a comprehensive range of products, including the Equil Patch insulin pump systems, AiDEX continuous glucose monitoring systems, POCT analyzer systems, traditional blood glucose monitoring systems, and advanced closed-loop artificial pancreas technology. Beyond its core offerings, MicroTech Medical is also actively involved in engineering and technological research, experimentation, and developmental endeavors. The firm, established in 2011, maintains its headquarters in Hangzhou, People's Republic of China.
IPO date
Oct 19, 2021
Employees
742
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT